#1 Clinical Trials Search in Europe

Gliquidone

This article delves into clinical trials investigating the use of Gliquidone, also known by its brand name Glurenorm®, in treating Type 2 Diabetes. We’ll explore how this medication compares to other treatments in terms of effectiveness and safety, particularly in Chinese patients who haven’t received previous diabetes treatment. The information provided will help patients better understand the ongoing research and potential benefits of Gliquidone in managing Type 2 Diabetes.

Table of Contents

Introduction to GLIQUIDONE

GLIQUIDONE, also known by its brand name Glurenorm®, is a medication used in the treatment of type 2 diabetes mellitus. This drug is part of a clinical trial comparing its effectiveness and safety with other diabetes medications in Chinese patients[1]. Type 2 diabetes is a chronic condition that affects how your body processes glucose (sugar), which is an important source of energy for your cells.

What is GLIQUIDONE?

GLIQUIDONE belongs to a class of medications called sulfonylureas. These drugs are used to help control blood sugar levels in people with type 2 diabetes. In the clinical trial, GLIQUIDONE (Glurenorm®) is being studied alongside other diabetes medications such as repaglinide and Glucobay®[1]. It’s important to note that GLIQUIDONE is specifically designed for patients with type 2 diabetes, not type 1 diabetes or other forms of the condition.

How GLIQUIDONE Works

GLIQUIDONE works by stimulating the pancreas to produce more insulin. Insulin is a hormone that helps your body’s cells absorb glucose from the bloodstream. By increasing insulin production, GLIQUIDONE helps lower blood sugar levels in people with type 2 diabetes. This mechanism of action is similar to other sulfonylurea drugs used in diabetes treatment[1].

Efficacy and Safety

The clinical trial mentioned in the source is designed to evaluate the efficacy and safety of GLIQUIDONE (Glurenorm®) compared to other diabetes medications. The study focuses on Chinese subjects with type 2 diabetes who have not previously received treatment for their condition[1]. The primary goal of the study is to assess how well these medications work after three months of treatment.

Some of the key aspects being evaluated include:

  • Fasting blood glucose: This measures the amount of glucose in your blood after an overnight fast. It’s an important indicator of how well your diabetes is being controlled[1].
  • Hypoglycemia episodes: These are instances when your blood sugar drops too low, which can be a side effect of diabetes medications. The study is monitoring how often these episodes occur with different treatments[1].

Comparison with Other Diabetes Medications

The clinical trial is comparing GLIQUIDONE (Glurenorm®) with two other diabetes medications:

  1. Repaglinide: This is another type of medication that stimulates insulin release from the pancreas, but it belongs to a different drug class called meglitinides[1].
  2. Glucobay®: This is the brand name for acarbose, which works differently from GLIQUIDONE. It slows down the digestion of carbohydrates in your intestines, which helps control blood sugar levels after meals[1].

By comparing these different medications, researchers hope to determine which treatment might be most effective and safe for Chinese patients with type 2 diabetes.

Potential Side Effects

While the clinical trial data doesn’t provide specific information about side effects, it’s important to be aware that all medications can have potential side effects. For sulfonylureas like GLIQUIDONE, one of the most significant potential side effects is hypoglycemia (low blood sugar), which is being specifically monitored in the study[1]. Symptoms of hypoglycemia can include shakiness, dizziness, sweating, and confusion. It’s crucial to discuss potential side effects with your healthcare provider and learn how to recognize and manage them.

Aspect Details
Study Title Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
Location Asia (focusing on Chinese subjects)
Medications Studied Repaglinide, Glurenorm® (Gliquidone), Glucobay®
Study Population Treatment-naive Chinese subjects with Type 2 Diabetes
Treatment Duration 3 months
Primary Measurements Fasting blood glucose, Hypoglycemia episodes
Study Aim Compare efficacy and safety of the three medications as mono-therapy

FAQ

  • What is Gliquidone (Glurenorm®)? Gliquidone, sold under the brand name Glurenorm®, is a medication used to treat Type 2 Diabetes. It belongs to a class of drugs that help control blood sugar levels in patients with this condition.
  • What was the main goal of the clinical trial involving Gliquidone? The main goal of the trial was to compare the effectiveness and safety of Gliquidone (Glurenorm®) with two other medications, repaglinide and Glucobay®, in Chinese patients with Type 2 Diabetes who had not received previous treatment.
  • How long did the treatment in the trial last? The trial evaluated the effects of the medications after 3 months of treatment.
  • What were the key measurements in the study? The study focused on measuring fasting blood glucose levels and monitoring the occurrence of hypoglycemia episodes (low blood sugar events) in the participants.
  • Where was this clinical trial conducted? This clinical trial was conducted in Asia, specifically focusing on Chinese subjects with Type 2 Diabetes.

Ongoing Clinical Trials on Gliquidone

  • Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

Glossary

  • Type 2 Diabetes: A chronic condition that affects the way your body processes blood sugar (glucose). It occurs when your body becomes resistant to insulin or doesn't produce enough insulin to maintain normal glucose levels.
  • Gliquidone (Glurenorm®): A medication used to treat Type 2 Diabetes by helping to control blood sugar levels.
  • Repaglinide: Another medication used to treat Type 2 Diabetes that works by stimulating the release of insulin from the pancreas.
  • Glucobay®: A brand name for acarbose, a medication that slows the digestion of carbohydrates to help control blood sugar levels in people with Type 2 Diabetes.
  • Mono-therapy: Treatment using a single drug, as opposed to combination therapy which uses multiple drugs.
  • Treatment-naive: Refers to patients who have not previously received treatment for a particular condition.
  • Fasting blood glucose: The level of sugar in your blood after an overnight fast, typically measured in the morning before eating.
  • Hypoglycemia: A condition characterized by abnormally low blood sugar levels, which can cause symptoms such as shakiness, dizziness, and confusion.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect.

References

  1. https://clinicaltrials.gov/study/NCT00568074